statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Study enrolling patients with metastatic urothelial cancer (mUC) and other Nectin-4 enriched tumorsEmerging clinical profile from CSPC's Phase 1 China study indicates differentiation from PADCEV...

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

This indicator may be signaling that CRBP's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Corbus Pharmaceuticals Holdings (CRBP, $37.79) entered Downtrend as Momentum indicator drops below 0 level on Mar 21, 2024

This is a Bearish indicator signaling CRBP's price could decline from here. Traders may explore shorting the stock or put options...

Corbus Pharmaceuticals Holdings (CRBP, $38.81) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 20, 2024

This is a signal that CRBP's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Corbus Pharmaceuticals Holdings (CRBP, $44.79) RSI Indicator left the overbought zone on March 14, 2024

Corbus Pharmaceuticals Holdings (CRBP, $47.08) RSI Indicator left the overbought zone on March 13, 2024

Encouraging CRB-701 (SYS6002) First-in-Human Data Presented at ASCO-GU 2024; first patient expected to be dosed in US Ph1 study by end of March 2024 IND Application for CRB-601 cleared; Ph1...

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP  Get Free Report) major shareholder Cormorant Asset Management, Lp bought 250,000 shares of the stock in a transaction that occurred on...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Major Shareholder Cormorant Asset Management, Lp Buys 250,000 Shares of Stock

Corbus Pharmaceuticals Holdings (CRBP, $38.27) RSI Indicator left the overbought zone on March 11, 2024

Corbus Pharmaceuticals Holdings (CRBP, $40.32) RSI Indicator left the overbought zone on March 07, 2024

This price move could be a signal that CRBP may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Corbus Pharmaceuticals Holdings (CRBP, $40.32) price may drop as it broke higher Bollinger Band on Mar 07, 2024

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.

Volume	53.00
52-Wk High	$49.87
52-Wk Low	$3.03

CRBP Corbus Pharmaceuticals Holdings Inc

About

Feed

News

Sentiment

Fundamentals

Sentiment

Message Volume

Community